Skip to main content

Table 2 Distribution of rs662799 (T1131C) polymorphism in the APOA5 gene in ESKD patients and healthy controls

From: Apolipoprotein A5 gene polymorphism (rs662799) and cardiovascular disease in end-stage kidney disease patients

 

Genotypes

MAF

OR (95% CI)a

N

TT

TC

CC

C allele

CC genotypeb

TC genotypeb

ESKD patients

800

644 (80.5)

128 (16)

28 (3.5)

0.12

1.26 (0.97–1.64)

2.25 (1.01–4.99)

1.07 (0.78–1.45)

      

p = 0.077

p = 0.045

p = 0.061

Controls

500

415 (83)

77 (15.4)

8 (1.6)

0.09

ref

ref

ref

  1. Genotype distribution is shown as numbers (%). Hardy–Weinberg equilibrium: χ2 = 3.335, p = 0.067 for control group
  2. ESKD End-stage kidney disease, APOA5 Apolipoprotein A5, MAF Minor allele frequency
  3. aAdjusted for age, sex, BMI, hypertension and diabetes
  4. bCalculated versus TT genotype